Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasm Metastasis 6Lymphoma, Extranodal NK-T-Cell 6Carcinoma, Hepatocellular 5Stomach Neoplasms 3Nasopharyngeal Carcinoma 3Locally Advanced Rectal Cancer 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Advanced Solid Tumor 3Triple Negative Breast Neoplasms 2Pancreatic Neoplasms 2Neoplasms 2Nasopharyngeal Neoplasms 2Melanoma 2Epstein-Barr Virus Infections 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Pancreatic Adenocarcinoma Metastatic 1Osteosarcoma 1Objective Response Rate 1NSCLC 1Muscle-Invasive Bladder Carcinoma 1Lymphoma, T-Cell 1Lymphoma 1Kidney Neoplasms 1Immunoblastic Lymphadenopathy 1

Interventions

spartalizumab 1Immunotherapy 1Granulocyte-Macrophage Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Objective Response Rate × spartalizumab × Clear all
NCT05760196 2023-03-08

Radiotherapy Combined With PD-1 Inhibitor and GM-CSF for Advanced Recurrent Metastatic Head and Neck Tumors

Renmin Hospital of Wuhan University

Phase 2 Unknown
56 enrolled

Objective Response Rate

Data powered by HemOnc (CC BY 4.0) Colophon âš¡